Donor ABCB1 variant associates with increased risk for kidney allograft failure

Journal of the American Society of Nephrology

Volumn 23, Issue 11, 2012, Pages 1891-1899

  Moore, Jason ^a,b   McKnight, Amy Jayne ^c   Döhler, Bernd ^d   Simmonds, Matthew J ^e   Courtney, Aisling E ^c   Brand, Oliver J ^e   Briggs, David ^f   Ball, Simon ^a,g   Cockwell, Paul ^a,g   Patterson, Christopher C ^c   Maxwell, Alexander P ^c   Gough, Stephen C L ^e   Opelz, Gerhard ^d   Borrows, Richard ^a,g  

^a QUEEN ELIZABETH HOSPITAL   (United Kingdom)

^b ROYAL DEVON AND EXETER NHS FOUNDATION TRUST   (United Kingdom)

^c QUEEN'S UNIVERSITY BELFAST   (United Kingdom)

^d UNIVERSITY OF HEIDELBERG   (Germany)

^e UNIVERSITY OF OXFORD   (United Kingdom)

^f NHS BLOOD AND TRANSPLANT   (United Kingdom)

^g UNIVERSITY OF BIRMINGHAM   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHILIN; CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; MULTIDRUG RESISTANCE PROTEIN 1; PREGNANE X RECEPTOR;

ABCB1 GENE; ADULT; ARTICLE; CONTROLLED STUDY; CYP3A4 GENE; CYP3A5 GENE; FEMALE; GENE; GENE LINKAGE DISEQUILIBRIUM; GENETIC ASSOCIATION; GENETIC RISK; GENETIC VARIABILITY; GENOTYPE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; KIDNEY ALLOGRAFT; KIDNEY ALLOGRAFT FAILURE; KIDNEY DONOR; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NR1I2 GENE; OUTCOME ASSESSMENT; PPIA GENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK ASSESSMENT; SINGLE NUCLEOTIDE POLYMORPHISM; UNITED KINGDOM;

EID: 84868621530     PISSN: 10466673     EISSN: 15333450     Source Type: Journal    
DOI: 10.1681/ASN.2012030260     Document Type: Article

References (39)

1. Naesens M, Kuypers DR, Sarwal M: Calcineurin inhibitor nephrotoxicity. Clin J Am Soc Nephrol 4: 481-508, 2009
2. Lown KS, Mayo RR, Leichtman AB, Hsiao HL, Turgeon DK, Schmiedlin-Ren P, Brown MB, Guo W, Rossi SJ, Benet LZ, Watkins PB: Role of intestinal P-glycoprotein (mdr1) in interpatient variation in the oral bioavailability of cyclosporine. Clin Pharmacol Ther 62: 248-260, 1997
3. Lemahieu WP, Maes BD, Verbeke K, Vanrenterghem YF: Alterations of CYP3A4 and P-glycoprotein activity in vivo with time in renal graft recipients. Kidney Int 66: 433-440, 2004
4. Wang H, LeCluyse EL: Role of orphan nuclear receptors in the regulation of drug-metabolising enzymes. Clin Pharmacokinet 42: 1331-1357, 2003
5. Zhang Y, Benet LZ: The gut as a barrier to drug absorption: Combined role of cytochrome P450 3A and P-glycoprotein. Clin Pharmacokinet 40: 159-68, 2001
6. Liu J, Farmer JD Jr, Lane WS, Friedman J, Weissman I, Schreiber SL: Calcineurin is a common target of cyclophilin-cyclosporin A and FKBPFK506 complexes. Cell 66: 807-815, 1991
7. Coto E, Tavira B: Pharmacogenetics of calcineurin inhibitors in renal transplantation. Transplantation 88: S62-S7, 2009
8. Macphee IA, Fredericks S, Tai T, Syrris P, Carter ND, Johnston A, Goldberg L, Holt DW: Tacrolimus pharmacogenetics: Polymorphisms associated with expression of cytochrome p4503A5 and P-glycoprotein correlate with dose requirement. Transplantation 74: 1486-1489, 2002
9. Tavira B, Coto E, Garciá EC, Díaz-Corte C, Ortega F, Arias M, Díaz JM, Selgas R, López-Larrea C, Campistol JM; REDINREN Pharmacogenetics group: et al.Pharmacogenetics of tacrolimus after renal transplantation: Analysis of polymorphisms in genes encoding 16 drug metabolizing enzymes. Clin Chem Lab Med 49: 825-833, 2011
10. Cattaneo D, Ruggenenti P, Baldelli S, Motterlini N, Gotti E, Sandrini S, Salvadori M, Segoloni G, Rigotti P, Donati D, Perico N, Remuzzi G; Mycophenolate Steroids Sparing (MYSS) Genetics Study Group: ABCB1 genotypes predict cyclosporine-related adverse events and kidney allograft outcome. J Am Soc Nephrol 20: 1404-1415, 2009
11. Bandur S, Petrasek J, Hribova P, Novotna E, Brabcova I, Viklicky O: Haplotypic structure of ABCB1/MDR1 gene modifies the risk of the acute allograft rejection in renal transplant recipients. Transplantation 86: 1206-1213, 2008
12. Grinyó J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, Rashford M, Nasmyth-Miller C, Voulgari A, Spleiss O, Truman M, Essioux L: Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 21: 879-891, 2008
13. Kreutz R, Bolbrinker J, van der Sman-de Beer F, Boeschoten EW, Dekker FW, Kain S, Martus P, Sietmann A, Friedrichs F, Stoll M, Offermann G, Beige J: CYP3A5 genotype is associated with longer patient survival after kidney transplantation and long-term treatment with cyclosporine. Pharmacogenomics J 8: 416-422, 2008
14. Goldfarb-Rumyantzev AS, Naiman N: Genetic prediction of renal transplant outcome. Curr Opin Nephrol Hypertens 17: 573-579, 2008
15. Joy MS, Nickeleit V, Hogan SL, Thompson BD, Finn WF: Calcineurin inhibitor-induced nephrotoxicity and renal expression of P-glycoprotein. Pharmacotherapy 25: 779-789, 2005
16. Joy MS, Hogan SL, Thompson BD, Finn WF, Nickeleit V: Cytochrome P450 3A5 expression in the kidneys of patientswith calcineurin inhibitor nephrotoxicity. Nephrol Dial Transplant 22: 1963-1968, 2007
17. Hauser IA, Schaeffeler E, Gauer S, Scheuermann EH, Wegner B, Gossmann J, Ackermann H, Seidl C, Hocher B, Zanger UM, Geiger H, Eichelbaum M, Schwab M: ABCB1 genotype of the donor but not of the recipient is a major risk factor for cyclosporine-related nephrotoxicity after renal transplantation. J Am Soc Nephrol 16: 1501-1511, 2005
18. Woillard JB, Rerolle JP, Picard N, Rousseau A, Guillaudeau A, Munteanu E, Essig M, Drouet M, Le Meur Y, Marquet P: Donor P-gp polymorphisms strongly influence renal function and graft loss in a cohort of renal transplant recipients on cyclosporine therapy in a long-term follow-up. Clin Pharmacol Ther 88: 95-100, 2010
19. Kimchi-Sarfaty C, Oh JM, Kim IW, Sauna ZE, Calcagno AM, Ambudkar SV, Gottesman MM: A "silent" polymorphism in the MDR1 gene changes substrate specificity. Science 315: 525-528, 2007
20. Altshuler DM, Gibbs RA, Peltonen L, Altshuler DM, Gibbs RA, Peltonen L, Dermitzakis E, Schaffner SF, Yu F, Peltonen L, Dermitzakis E, Bonnen PE, Altshuler DM, Gibbs RA, de Bakker PI, Deloukas P, Gabriel SB, Gwilliam R, Hunt S, Inouye M, Jia X, Palotie A, Parkin M, Whittaker P, Yu F, Chang K, Hawes A, Lewis LR, Ren Y, Wheeler D, Gibbs RA, Muzny DM, Barnes C, Darvishi K, Hurles M, Korn JM, Kristiansson K, Lee C, McCarrol SA, Nemesh J, Dermitzakis E, Keinan A, Montgomery SB, Pollack S, Price AL, Soranzo N, Bonnen PE, Gibbs RA, Gonzaga-Jauregui C, Keinan A, Price AL, Yu F, Anttila V, Brodeur W, Daly MJ, Leslie S, McVean G, Moutsianas L, Nguyen H, Schaffner SF, Zhang Q, Ghori MJ, McGinnis R, McLaren W, Pollack S, Price AL, Schaffner SF, Takeuchi F, Grossman SR, Shlyakhter I, Hostetter EB, Sabeti PC, Adebamowo CA, Foster MW, Gordon DR, Licinio J, Manca MC, Marshall PA, Matsuda I, Ngare D, Wang VO, Reddy D, Rotimi CN, Royal CD, Sharp RR, Zeng C, Brooks LD, McEwen JE; International HapMap 3 Consortium: Integrating common and rare genetic variation in diverse human populations. Nature 467: 52-58, 2010
21. Naesens M, Lerut E, de Jonge H, Van Damme B, Vanrenterghem Y, Kuypers DR: Donor age and renal P-glycoprotein expression associate with chronic histological damage in renal allografts. J Am Soc Nephrol 20: 2468-2480, 2009
22. Cosio FG, Grande JP, Wadei H, Larson TS, Griffin MD, Stegall MD: Predicting subsequent decline in kidney allograft function from early surveillance biopsies. Am J Transplant 5: 2464-2472, 2005
23. Nankivell BJ, Fenton-Lee CA, Kuypers DR, Cheung E, Allen RD, O'Connell PJ, Chapman JR: Effect of histological damage on long-term kidney transplant outcome. Transplantation 71: 515-523, 2001
24. Nankivell BJ, Borrows RJ, Fung CL, O'Connell PJ, Chapman JR, Allen RD: Calcineurin inhibitor nephrotoxicity: Longitudinal assessment by protocol histology. Transplantation 78: 557-565, 2004
25. Woodahl EL, Ho RJ: The role of MDR1 genetic polymorphisms in interindividual variability in P-glycoprotein expression and function. Curr Drug Metab 5: 11-19, 2004
26. Katoh SY, Ueno M, Takakura N: Involvement of MDR1 function in proliferation of tumour cells. J Biochem 143: 517-524, 2008
27. Robinson LJ, Roberts WK, Ling TT, Lamming D, Sternberg SS, Roepe PD: Human MDR 1 protein overexpression delays the apoptotic cascade in Chinese hamster ovary fibroblasts. Biochemistry 36: 11169-11178, 1997
28. Petruzzo P, Cappai A, Brotzu G, Batetta B, Putzolu M, Mulas MF, Bonatesta RR, Sanna F, Dessì S: Lipid metabolism and molecular changes in normal and atherosclerotic vessels. Eur J Vasc Endovasc Surg 22: 31-36, 2001
29. Huls M, Kramers C, Levtchenko EN, Wilmer MJ, Dijkman HB, Kluijtmans LA, van der Hoorn JW, Russel FG, Masereeuw R: P-glycoprotein-deficient mice have proximal tubule dysfunction but are protected against ischemic renal injury. Kidney Int 72: 1233-1241, 2007
30. Huls M, Schoeber JP, Verfaillie CM, Luttun A, Ulloa-Montoya F, Menke AL, van Bolderen LR, Woestenenk RM, Merkx GF, Wetzels JF, Russel FG, Masereeuw R: Deficiency of either P-glycoprotein or breast cancer resistance protein protect against acute kidney injury. Cell Transplant 19: 1195-1208, 2010
31. Oliver JA, Maarouf O, Cheema FH, Martens TP, Al-Awqati Q: The renal papilla is a niche for adult kidney stemcells. J Clin Invest 114: 795-804, 2004
32. Kim J, Kim JI, Na YK, Park KM: Intra-renal slow cell-cycle cells contribute to the restoration of kidney tubules injured by ischemia/reperfusion. Anat Cell Biol 44: 186-193, 2011
33. Hebert MF, Dowling AL, Gierwatowski C, Lin YS, Edwards KL, Davis CL, Marsh CL, Schuetz EG, Thummel KE: Association between ABCB1 (multidrug resistance transporter) genotype and post-liver transplantation renal dysfunction in patients receiving calcineurin inhibitors. Pharmacogenetics 13: 661-674, 2003
34. Anglicheau D, Thervet E, Etienne I, Hurault De Ligny B, Le Meur Y, Touchard G, Büchler M, Laurent-Puig P, Tregouet D, Beaune P, Daly A, Legendre C, Marquet P: CYP3A5 and MDR1 genetic polymorphisms and cyclosporine pharmacokinetics after renal transplantation. Clin Pharmacol Ther 75: 422-433, 2004
35. Crettol S, Venetz JP, Fontana M, Aubert JD, Ansermot N, Fathi M, Pascual M, Eap CB: Influence of ABCB1 genetic polymorphisms on cyclosporine intracellular concentration in transplant recipients. Pharmacogenet Genomics 18: 307-315, 2008
36. Moscoso-Solorzano GT, Ortega F, Rodríguez I, García-Castro M, Gómez E, Díaz-Corte C, Baltar JM, Alvarez V, Ortiz A, Coto E: A search for cyclophilin-A gene variants in cyclosporine A-treated renal transplanted patients. Clin Transplant 22: 722-729, 2008
37. Dring MM, Goulding CA, Trimble VI, Keegan D, Ryan AW, Brophy KM, Smyth CM, Keeling PW, O'Donoghue D, O'Sullivan M, O'Morain C, Mahmud N, Wikström AC, Kelleher D, McManus R: The pregnane X receptor locus is associated with susceptibility to inflammatory bowel disease. Gastroenterology 130: 341-348, quiz 592, 2006
38. Martínez A, Márquez A, Mendoza J, Taxonera C, Fernández-Arquero M, Díaz-Rubio M, de la Concha EG, Urcelay E: Role of the PXR gene locus in inflammatory bowel diseases. Inflamm Bowel Dis 13: 1484-1487, 2007
39. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, Higgins J, DeFelice M, Lochner A, Faggart M, Liu-Cordero SN, Rotimi C, Adeyemo A, Cooper R, Ward R, Lander ES, Daly MJ, Altshuler D: The structure of haplotype blocks in the human genome. Science 296: 2225-2229, 2002